All In Biotech

Free tool

FAERS Monitor: Zembrace Symtouch (Autoinjector)

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 208223 or its brand name (Zembrace Symtouch (Autoinjector), Sumatriptan Succinate). Reports on generic versions are filed under their own applications.

Reports

7,926

Serious

3,886

49% of reports

Hospitalization

1,391

Death reported

216

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective1,185
  • headache793
  • migraine664
  • nausea591
  • product dose omission issue574
  • fatigue503
  • off label use456
  • product quality issue433
  • device malfunction404
  • pain383
  • dizziness371
  • product complaint349
  • drug intolerance335
  • dyspnoea321
  • vomiting300

Reports by year received

View as table
YearReports
200447
200554
200657
200799
200881
2009175
2010425
2011296
2012195
2013148
2014170
2015213
2016444
2017294
2018377
2019387
2020565
2021524
2022558
2023695
2024664
2025602
2026856

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,046,233 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
product complaintSignal34937.033.412,051
migraineSignal66418.617.311,001
device malfunctionSignal40415.313.95,388
drug intoleranceSignal3359.28.32,453
product quality issueSignal4338.57.72,860
product dose omission issueSignal5745.24.81,960
headacheSignal7933.43.11,350
drug ineffectiveSignal1,1852.42.31,017
nausea5912.01.8298
dizziness3712.01.8182
fatigue5031.71.6155
vomiting3001.71.586
pain3831.71.5102
dyspnoea3211.51.455
off label use4561.41.350

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.